The patents for some GLP-1 drugs are set to expire in the coming years, including: Victoza (liraglutide): The patent for this drug expired in late 2023, allowing companies to pursue generic versions. Xultophy (liraglutide–insulin degludec): The patent for this drug is set to expire on November 18, 2024.
Trulicity: The U.S. patent for this drug is set to expire in 2027. Semaglutide (Wegovy): The patent for this drug is set to expire on March 20, 2026. However, Novo Nordisk is working to extend its exclusivity by adding other patents.
Victoza (liraglutide): The patent for this drug expired in late 2023, allowing companies to pursue generic versions.
Xultophy (liraglutide–insulin degludec): The patent for this drug is set to expire on November 18, 2024.
Semaglutide (Wegovy): The patent for this drug is set to expire on March 20, 2026. However, Novo Nordisk is working to extend its exclusivity by adding other patents.